Despite being first to market with CAR-T therapy, Kymriah's commercial performance has consistently disappointed relative to initial expectations due to manufacturing complexity, patient eligibility constraints, and competitive pressure from Gilead's Yescarta. The launch highlighted the gap between scientific innovation and commercial execution in cell therapy.